• Mutation; HGNC; HGNC:5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line).
  

PubMed=15520187; DOI=10.1158/0008-5472.CAN-04-0826
Nicholson B.E., Frierson H.F. Jr., Conaway M.R., Seraj J.M., Harding M.A., Hampton G.M., Theodorescu D.
Profiling the evolution of human metastatic bladder cancer.
Cancer Res. 64:7813-7821(2004)

PubMed=19147813; DOI=10.2353/ajpath.2009.080538; PMCID=PMC2630547
Smith S.C., Nicholson B., Nitz M.D., Frierson H.F. Jr., Smolkin M., Hampton G.M., El-Rifai W., Theodorescu D.
Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination.
Am. J. Pathol. 174:371-379(2009)

PubMed=24376083; DOI=10.1002/pmic.201300452
Jeppesen D.K., Nawrocki A., Jensen S.G., Thorsen K., Whitehead B., Howard K.A., Dyrskjot L., Orntoft T.F., Larsen M.R., Ostenfeld M.S.
Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.
Proteomics 14:699-712(2014)

PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)